Acute pain

Global Chronic Pain Treatment Market to 2024 - Market is Expected to Exceed $100+ Billion

Retrieved on: 
Thursday, February 7, 2019

Chronic pain treatment market is expected to reach $105.9 billion by 2024, the market growth is primarily driven by the rising prevalence of chronic conditions, surging geriatric population, and increasing government support toward chronic pain management.

Key Points: 
  • Chronic pain treatment market is expected to reach $105.9 billion by 2024, the market growth is primarily driven by the rising prevalence of chronic conditions, surging geriatric population, and increasing government support toward chronic pain management.
  • On basis of indication, the chronic pain treatment market is categorized into neuropathic pain, arthritis pain, cancer pain, chronic back pain, migraine, fibromyalgia, and others.
  • Hospitals; clinics; nursing homes; and research centers and universities are the major end users in the chronic pain treatment market.
  • During the forecast period, the chronic pain treatment market is expected to witness the fastest growth in the APAC region.

GEMCO Medical Introduces the GEMCORE360˚™ Brand of Advanced Wound Care Products

Retrieved on: 
Tuesday, February 5, 2019

HUDSON, Ohio, Feb. 5, 2019 /PRNewswire/ --GEMCO Medical, a national distributor of medical products, is pleased to announce the addition of the GEMCORE360 brand of advanced wound care products.

Key Points: 
  • HUDSON, Ohio, Feb. 5, 2019 /PRNewswire/ --GEMCO Medical, a national distributor of medical products, is pleased to announce the addition of the GEMCORE360 brand of advanced wound care products.
  • GEMCORE360Advanced Wound Care offers healthcare professionals a simple, clear and cost-effective wound care range while ensuring excellent clinical outcomes for their patients.
  • "Our new wound care line is a great complement to the existing product lines we distribute," said Rich Keirn, Vice President/General Manager of GEMCO Medical.
  • GEMCO Medical, Inc., founded in 1992 and headquartered in Hudson, Ohio, is a leading wholesale distributor and logistics provider of a broad selection of quality, dependable medical products.

Angina (Angina Pectoris) - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 1, 2019

The "Angina (Angina Pectoris) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Angina (Angina Pectoris) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Angina (Angina Pectoris) development.
  • The report covers pipeline activity across the complete product development cycle i.e.
  • clinical, pre-clinical and discovery stages for the Angina (Angina Pectoris)
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Angina (Angina Pectoris)
    Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

Leading Edge Pharms Adds New Pain Relief Ointment to CANNAVERA™ Product Line

Retrieved on: 
Tuesday, January 29, 2019

HENDERSON,Nevada, Jan. 29, 2019 /PRNewswire/ -- Leading Edge Pharms, Inc. (LEP), a biotechnology company developing novel cannabinoid therapies and innovative delivery systems, announced the launch of a new pain relief ointment in their existing CANNAVERA product line of topical pain relief creams, sprays and oils.

Key Points: 
  • HENDERSON,Nevada, Jan. 29, 2019 /PRNewswire/ -- Leading Edge Pharms, Inc. (LEP), a biotechnology company developing novel cannabinoid therapies and innovative delivery systems, announced the launch of a new pain relief ointment in their existing CANNAVERA product line of topical pain relief creams, sprays and oils.
  • "Our new topical pain relief ointment provides another application option for our proven THC-free pain management treatments.
  • Responding to consumer requests, Leading Edge Pharms has also released smaller sizes of its existing CANNAVERA cream and spray.
  • LEP is the developer of CANNAVERA pain relief products, available in pharmacies across the United States.

“Smarter” Genetic Risk Testing from RDx BioScience Enhances Safe, Cost Effective Pain Management and High-Quality Addiction Care

Retrieved on: 
Tuesday, January 29, 2019

RDx BioScience (RDx) , a single source for care quality, risk evaluation and opioid expertise powered by a fast, full-service laboratory, points to the important role of pharmacogenomic (PGx) testing in the workplace, optimizing safe, cost-effective pain management and addiction treatment to help address issues related to opioid addiction.

Key Points: 
  • RDx BioScience (RDx) , a single source for care quality, risk evaluation and opioid expertise powered by a fast, full-service laboratory, points to the important role of pharmacogenomic (PGx) testing in the workplace, optimizing safe, cost-effective pain management and addiction treatment to help address issues related to opioid addiction.
  • With fifty percent of opioid addiction cases related to an individuals genetic factors, PGx testing impacts patients pain relief responses and their likelihood of developing adverse drug effects and drug addiction.
  • Chronic pain resulting from workplace injuries and associated opioid prescribing to manage pain poses important economic burdens and public health issues.
  • RDx supports the Task Forces Pain Management Best Practices by utilizing our specialized expertise in opioid addiction to improve care for those suffering from acute and chronic pain.

Pain Management Therapeutics Market Will Become Worth US$88,253.4 Million by 2025, Says TMR

Retrieved on: 
Tuesday, January 29, 2019

Region wise, North America is expected to lead the global pain management therapeutics market in the coming years.

Key Points: 
  • Region wise, North America is expected to lead the global pain management therapeutics market in the coming years.
  • Along with this, rapid changing lifestyles, burgeoning population, and rising cases of chronic pain globally are driving the global pain management therapeutics market.
  • Transparency Market Research (TMR) notes that the global pain management therapeutics market is categorized by the presence of several large and small players operating in it.
  • Popular Research Reports by TMR:
    Topical Pain Management Therapeutics in Sports Medicine Market: https://www.transparencymarketresearch.com/topical-pain-management-thera...
    Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services.

Pain Management Therapeutics Market Will Become Worth US$88,253.4 Million by 2025, Says TMR

Retrieved on: 
Tuesday, January 29, 2019

Region wise, North America is expected to lead the global pain management therapeutics market in the coming years.

Key Points: 
  • Region wise, North America is expected to lead the global pain management therapeutics market in the coming years.
  • Along with this, rapid changing lifestyles, burgeoning population, and rising cases of chronic pain globally are driving the global pain management therapeutics market.
  • Transparency Market Research (TMR) notes that the global pain management therapeutics market is categorized by the presence of several large and small players operating in it.
  • Popular Research Reports by TMR:
    Topical Pain Management Therapeutics in Sports Medicine Market: https://www.transparencymarketresearch.com/topical-pain-management-thera...
    Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services.

Diabetic Neuropathic Pain Report - Pipeline Insights 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 25, 2019

The "Diabetic Neuropathic Pain - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diabetic Neuropathic Pain - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • "Diabetic Neuropathic Pain - Pipeline Insight, 2019 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Diabetic Neuropathic Pain development.
  • The report assesses the active Diabetic Neuropathic Pain pipeline products by developmental stage, product type, molecule type, and administration route.
  • clinical, pre-clinical and discovery stages for the Diabetic Neuropathic Pain
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Diabetic Neuropathic Pain

Motivational Speaking Team Of Catastrophically Wounded Combat Vets From Wars In Iraq And Afghanistan Launches

Retrieved on: 
Thursday, January 24, 2019

CHARLOTTE, N.C., Jan. 24, 2019 /PRNewswire/ --Today, the Tiger Team 7, a unit of catastrophically wounded combat Veterans from wars in Iraq and Afghanistan, has been launched.

Key Points: 
  • CHARLOTTE, N.C., Jan. 24, 2019 /PRNewswire/ --Today, the Tiger Team 7, a unit of catastrophically wounded combat Veterans from wars in Iraq and Afghanistan, has been launched.
  • Mike Verardo (34); Army infantryman with the 82nd Airborne; combat wounded April 2010 in Afghanistan; left leg above-the-knee amputation; left arm reattached; TBI.
  • John Masson (47); Army Master Sergeant; combat wounded October 2010 in Afghanistan; triple amputee, both legs and left arm.
  • Michael Boucher (29); Marine Corporal combat engineer; combat wounded June 2011 in Afghanistan; double amputee, both legs above-the-knee; severe injuries to left hand.

Americans’ Financial Satisfaction Drops for the First Time in 2 Years: AICPA Index

Retrieved on: 
Thursday, January 24, 2019

With a reading of 30.9, the AICPAs Q4 2018 Personal Financial Satisfaction Index (PFSi) declined for the first time in seven quarters, ending its five-quarter run of consecutive record highs.

Key Points: 
  • With a reading of 30.9, the AICPAs Q4 2018 Personal Financial Satisfaction Index (PFSi) declined for the first time in seven quarters, ending its five-quarter run of consecutive record highs.
  • View the full release here: https://www.businesswire.com/news/home/20190124005017/en/
    Q4 2018 PFSi Infographic (Graphic: Business Wire)
    The PFSi is calculated as the Personal Financial Pleasure Index (Pleasure Index) minus the Personal Financial Pain Index (Pain Index), with positive readings signaling that Americans are feeling more financial pleasure than pain.
  • The Pain Index, at 39.3, saw three factors decrease from the previous quarter, combining to drop the index 2.6 points.
  • It is calculated as the difference between the Personal Financial Pleasure Index and the Personal Financial Pain Index.